The arrest and indictment will buttress the efforts of more established pharmaceutical companies to distance themselves from the upstart “He is not us,” Kenneth C. Frazier, chief executive of Merck and chairman of the pharmaceutical industry’s main trade group, said this month at the Forbes Healthcare Summit this month. Now, pharmaceutical executives can look at the federal indictment and say that Mr. Shkreli is an aberration, a rotten apple.